GlassScriptPhysician profile
James N Jacobson
NPI 1558391110
$66,776.70
in general payments reported to CMS, 2019-2025
24 companies · $4,535 in 2025
The $4,535 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,145 · 2021: $3,891 · 2022: $8,079 · 2023: $3,722 · 2024: $9,009 · 2025: $4,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,280 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,450 · Food and Beverage: $2,371 · Travel and Lodging: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,280.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,450.00 |
| Food and Beverage | $2,370.76 |
| Travel and Lodging | $1,165.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29,769.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $12,120.79 | 2024-2025 | Cobenfy |
| Abbvie INC. | $11,733.71 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $9,337.78 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,565.67 | 2020-2025 | Caplyta |
| Neuronetics, INC. | $987.60 | 2019-2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $235.45 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $167.87 | 2020-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Axsome Therapeutics, INC. | $132.36 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $119.83 | 2022-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $104.07 | 2019-2024 | Spravato |
| Janssen Scientific Affairs, LLC | $100.61 | 2023 | Spravato |
| Lundbeck LLC | $93.21 | 2019-2021 | |
| Livanova USA, INC. | $79.35 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $46.17 | 2022-2024 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $44.95 | 2022-2024 | Lybalvi |
| Orexo US, INC. | $21.06 | 2022 | |
| Corium, LLC | $19.68 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $17.75 | 2022 | |
| Tris Pharma INC | $17.08 | 2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $16.93 | 2019 | |
| Eisai INC. | $16.07 | 2020 | |
| Indivior INC. | $15.05 | 2020 | |
| Alfasigma USA, INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.